Efficacy of sorafenib in patients with gastrointestinal stromal tumors in the third- or fourth-line treatment: A retrospective multicenter experience

Basit Öğe Kaydı
dc.authoridKEFELI, UMUT/0000-0001-6126-5377
dc.authoridbenekli, mustafa/0000-0003-3184-4946
dc.authoridharputluoglu, hakan/0000-0001-8537-5941
dc.authoridSevinç, Alper/0000-0002-0499-8918
dc.authoridOzturk, Banu/0000-0003-0290-8787
dc.authoridkaya, ali o/0000-0001-7182-6641
dc.authoridDEMIRCI, UMUT/0000-0002-4833-6721
dc.authorwosidGumus, Mahmut/C-7135-2008
dc.authorwosidKAYA, Ali/KFA-9478-2024
dc.authorwosidKEFELI, UMUT/V-6023-2017
dc.authorwosidGumus, Mahmut/HTO-4176-2023
dc.authorwosidDurnalı, Ayşe/ABC-2229-2021
dc.authorwosidDurnalı, Ayşe/AAZ-8847-2021
dc.authorwosidSevinc, Alper/KFQ-6440-2024
dc.contributor.authorKefeli, Umut
dc.contributor.authorBenekli, Mustafa
dc.contributor.authorSevinc, Alper
dc.contributor.authorYildiz, Ramazan
dc.contributor.authorKaplan, Muhammed Ali
dc.contributor.authorCiltas, Aydin
dc.contributor.authorBalakan, Ozan
dc.date.accessioned2024-08-04T20:37:42Z
dc.date.available2024-08-04T20:37:42Z
dc.date.issued2013
dc.departmentİnönü Üniversitesien_US
dc.description.abstractSorafenib is a multi-targeted tyrosine kinase receptor inhibitor used to treat patients with advanced gastrointestinal stromal tumors (GISTs). The present study evaluated the efficacy and tolerability of sorafenib therapy for patients with GISTs. Between January 2001 and November 2012, 25 patients, from multiple centers, who had received sorafenib as the third-or fourth-line treatment for GISTs were investigated retrospectively. In total, 17 patients were male and eight were female. The median age was 54.0 years (range, 16-82 years). From the patients, 21 received imatinib for longer than six months and four received it for less than six months. The clinical benefit rate of sorafenib was 40.0%. Treatment-related adverse events were reported in 72% of patients. These adverse events were generally mild to moderate in intensity. The median progression-free survival (PFS) and overall survival (OS) times of the patients who received sorafenib were 7.2 and 15.2 months, respectively. The duration of imatinib usage was an independent prognostic factor for PFS and OS. Sorafenib is an effective treatment in patients with GISTs showing a clinical benefit rate of 40.0% and an acceptable tolerability.en_US
dc.identifier.doi10.3892/ol.2013.1408
dc.identifier.endpage611en_US
dc.identifier.issn1792-1074
dc.identifier.issn1792-1082
dc.identifier.issue2en_US
dc.identifier.pmid24137379en_US
dc.identifier.scopus2-s2.0-84879473922en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage605en_US
dc.identifier.urihttps://doi.org/10.3892/ol.2013.1408
dc.identifier.urihttps://hdl.handle.net/11616/96111
dc.identifier.volume6en_US
dc.identifier.wosWOS:000322381000060en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpandidos Publ Ltden_US
dc.relation.ispartofOncology Lettersen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectsorafeniben_US
dc.subjectgastrointestinal stromal tumorsen_US
dc.subjectefficacyen_US
dc.titleEfficacy of sorafenib in patients with gastrointestinal stromal tumors in the third- or fourth-line treatment: A retrospective multicenter experienceen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu